Pacegenix, Inc.

CAMBRIDGE, MA · Founded 2024 · CIK 0002117706 · Medtech · Private

Cardiac pacemaker software or algorithms for arrhythmia detection and management

— →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$23M
1 Form D · Mar 2026
6 months since last filing
Contracts
—
No federal contracts on record
Patents
5
0 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$22,533,267
Form D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1474Neurosity, Inc.—$5.0M
1475Nanopath—$15M
1476BoldHue, Inc.—$3.4M
1477Pacegenix, Inc.—$23M
1478Peak Mind Inc.—$20K
1479Exokinetics, Inc.—$100K
1480Vista Robotics, Inc.—$275K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Fredric EshelmanDirector
  • Frank Grazzini, IIExecutive Officer
  • Raymond TabibiazarDirector
  • Jay WohlgemuthDirector · Executive Officer

Patents

USPTO · 0 granted of 5
  • Compounds Suitable For Cardiovascular Disease Treatmentapplication
  • Compounds Suitable For Cardiovascular Disease Or Disorder Treatmentapplication
  • Compounds suitable for cardiovascular disease treatmentapplication
  • (S)-sec-butyl 2-(3-(4-(2-(diethylamino)ethoxy)-3,5-diiodobenzoyl)benzofuran-2-yl) acetate prodrugs and uses thereofapplication
  • Compounds Suitable For Cardiovascular Disease Or Disorder Treatmentapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.